[1]ÂíÈåÁÖ£¬¹ùÊçϼ£¬Àîåû£¬µÈ. н®¹þÈø¿Ë×å³ÉÈËѪ֬Òì³£¼°ÆäÓ°ÏìÒòËØ[J].Öйú¹«¹²ÎÀÉú£¬2012£¬28(8): 1009-1013.
[2]»ÆÎľü£¬Áõ¿¡Ã÷£¬Ð»Î°£¬µÈ. ºº×塢άÎá¶û×å¡¢¹þÈø¿Ë×å¹ÚÐIJ¡»¼Õß¹Ú×´¶¯Âö²¡±äµÄÁÙ´²Ñо¿[J]. Öйú½éÈëÐÄÔಡѧÔÓÖ¾£¬2012£¬20(4): 212-216.
[3]Carbone F£¬Nencioni A£¬Mach F£¬et al. Pathophysiological role of neutrophils in acute myocardial infarction£ÛJ£Ý.Thromb Haemost£¬2013£¬110£¨3£©£º501-514.
[4]ÍõÑ×£¬ÁõÓ¢£¬Ð»çâÀò£¬µÈ. ¹ÚÐIJ¡»¼ÕßѪÇåð°Î²ËØÓë¹Ú×´¶¯Âö²¡±äÑÏÖØ³Ì¶ÈÏà¹ØÐÔ·ÖÎö£ÛJ£Ý£®¶«ÄϹú·ÀÒ½Ò©£¬2016£¬18 (4)£º 382-384.
[5]Y¢clmaz S, Canpolat U, Ba ÿðþ ‰D er K£¬et al. Neutrophil-to-lymphocyte ratio predicts functionally significant coronary artery stenosis in patients with stable coronary artery disease£ÛJ£Ý.Turk Kardiyol Dern Ars£¬2018£¬46(2):129-135.
[6]Seaoud E, Mohamed AAHA, Elkot MA. The Role of the Platelet/Lymphocyte Ratio and Neutrophil/Lymphocyte Ratio in Predicting High-Risk Heart Score in Patients Admitted with Non-ST Elevation Acute Coronary Syndrome£ÛJ£Ý.Pulse (Basel)£¬2020£¬8(1-2):66-74.
[7]Afari ME£¬Bhat T.Neutrophil to lymphocyte ratio£¨NLR£©and cardiovascular diseases£ºan update£ÛJ£Ý.Expert Rev Cardiovasc Ther£¬2016£¬14£¨5£©£º573-577.
[8]Li XL, Ji YL, Kang JH£¬et al.Association between blood neutrophil-to-lymphocyte ratio and severity of coronary artery disease: Evidence from 17 observational studies involving 7017 cases£ÛJ£Ý.Medicine (Baltimore)£¬2018£¬97(39):e12432. doi: 10.1097/MD.0000000000012432.
[9]Tan¢cnd¢c A£¬Erkan AF£¬Ekici B£¬et al. Neutrophil to lymphocyte ratio is associated with more extensive£¬severe and complex coronary artery disease and impaired myocardial perfusion£ÛJ£Ý.Turk Kardiyol Dern Ars£¬2014£¬42£¨2£©£º125-130.
[10]Gersini GG.A more meaningful scoring system for determining the severity of coronary heart disease[J].Am J Cardiol,1983£¬51(3):606.
[11]ÑîÀû¾ê£¬Íõóã÷.ÖÐÐÔÁ£Ï¸°ûÁܰÍϸ°û±ÈÖµÔÚÆÀ¹ÀÐŦÄÜÑÏÖØ³Ì¶ÈÖеÄÓ¦ÓÃ[J]£®ÖйúÑÖ¤ÐÄѪ¹ÜҽѧÔÓÖ¾£¬2017£¬9(1): 60-62.
[12]Yang Y, Xu YN, Wang J, et al.Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in new onset acute coronary syndrome: a retrospective cohort study[J]. BMC Cardiovasc Disord,2020,20(1):500.
[13]Dong CH, Wang ZM, Chen SY. Neutrophil to lymphocyte ratio predict mortality and major adverse cardiac events in acute coronary syndrome: A systematic review and meta-analysis[J]. Clin Biochem,2018,52:131-136.
[14]Verdoia M, Barbieri L, Di Giovine G£¬et al.Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results From a Large Cohort Study[J]. Angiology£¬2016 £¬67(1):75-82.
[15]Kounis NG, Soufras GD, Tsigkas G£¬et al. White blood cell counts, leukocyte ratios, and eosinophils as inflammatory markers in patients with coronary artery disease[J]. Clin Appl Thromb Hemost£¬2015£¬21(2):139-143.
[16]Balta S, Celik T, Mikhailidis DP,et al.The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio[J]. Clin Appl Thromb Hemost£¬2016£¬22(5):405-411.
[17]Demirkol S£¬Balta S£¬Unlu M£¬et al.Neutrophils/lymphocytes ratio in patients with cardiac syndrome X and its association with carotid intima-media thickness[J]. Clin Appl Thromb Hemost£¬2014£¬20 (3):250-255.
[18]Balta I£¬Balta S£¬Koryurek OM£¬et al.Serum endocan levels as a marker of disease activity in patients with Beh¢“et disease£ÛJ£Ý.Am Acad Dermatol£¬2014£¬70 (2):291-296.
[19]Marchini T, Mitre LS, Wolf D. Inflammatory Cell Recruitment in Cardiovascular Disease[J]. Front Cell Dev Biol£¬2021£¬9:635527. doi: 10.3389/fcell.2021.635527.
[20]Balta S£¬Kurtoglu E£¬Kucuk U£¬et al.Neutrophil-lymphocyte ratio as an important assessment tool[J]. Expert Rev Cardiovasc Ther£¬2014£¬12 (5):537-538.
[21]Karaman M, Balta S, Seyit Ahmet AY,et al. The comparative effects of valsartan and amlodipine on vWf Levels and N/L ratio in patients with newly diagnosed hypertension[J]. Clin Exp Hypertens£¬2013£¬35 (7):516-522.
[22]Akin F£¬Ay¢“a B£¬K¢‰se N.Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia[J]. Angiology£¬2013£¬64 (8):621-625.
[23]Fici F£¬Celik T£¬Balta S£¬et al.Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension[J]. Cardiovasc Pharmacol£¬2013£¬62 (4):388-393.
[24]½ð½à£¬Íõ¿¡£¬ÍõÀÚ£¬µÈ. ¹ÚÐIJ¡»¼ÕßѪÇåͬÐͰëë×°±Ëá¡¢£í£é£Ò-£±¡¢£í£é£Ò-£±£²£¶ ºÍ £í£é£Ò-£²£°£¸ µÄÏà¹ØÐÔ·ÖÎö[J].¶«ÄϹú·ÀÒ½Ò©£¬2014£¬16(4): 363-366.
[1]´÷»Ü,ÕÅ•¥,çÑСºì,µÈ.ÖÐÐÔÁ£Ï¸°û/ÁܰÍϸ°û±ÈÖµÁªºÏÓªÑø·çÏÕɸ²é¶ÔÀÏÄ꼡ÉÙÖ¢»¼ÕßµÄÕï¶Ï¼ÛÖµ[J].ҽѧÑо¿ÓëÕ½´´É˾ÈÖÎ(ÔҽѧÑо¿Éúѧ±¨),2023,25(3):242.[doi:10.3969/j.issn.1672-271X.2023.03.004]
¡¡DAI Hui,ZHANG Wei,MIAO Xiaohong,et al.The diagnostic value of neutrophil/lymphocyte ratio combined with nutritional risk screening in senile patients with sarcopenia[J].JOURNAL OF MEDICALRESEARCH ¡ªCOMBAT TRAUMA CARE,2023,25(05):242.[doi:10.3969/j.issn.1672-271X.2023.03.004]